drug pricing

The patient is the point: The changing landscape innovation in drug development

Bringing in market access and collaboration earlier in the process, viewing reimbursement as the last leg of the drug developmental journey, and collaborating across key functions are practices we can evolve so that as many patients as possible can reap the rewards that are waiting for them.

Biden brings plan for prescription drug pricing reform to Congress

That is the title of an article published in Pharmaceutical Technology today. I am quoted extensively. For instance, President Biden proposes to cap drug prices at genera rates of inflation. The article highlights some limits this would pose to value-based pricing that could evolve over time: Shafrin also says while Biden’s plan to penalise companies …

Biden brings plan for prescription drug pricing reform to Congress Read More »

Pfizer, Flynn in the firing line again over UK epilepsy drug pricing

The UK’s Competition and Markets Authority (CMA) has resurrected a complaint against Pfizer and Flynn Pharma, claiming the two companies charged the NHS excessive prices for a widely-used epilepsy therapy. In a provisional judgment, the CMA has concluded that Pfizer and Flynn abused a dominant position to overcharge the NHS for phenytoin sodium capsules, causing …

Pfizer, Flynn in the firing line again over UK epilepsy drug pricing Read More »

Community Health Plans Are Serious: Support Major Federal Action to Reduce Rx Drug Costs

By CECI CONNOLLY Equal treatment under the law. A foundational pillar of American life. Except when it comes to drug makers who benefit from favorable treatment by the federal government. For far too long, prescription drug companies have profited immensely under a system that affords them monopolistic powers to set prices devoid of government or …

Community Health Plans Are Serious: Support Major Federal Action to Reduce Rx Drug Costs Read More »

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities

As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn, explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying that if pharmaceutical companies are not profitable, they will not survive. The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are …

Pricing, Profits and Progress: Pharma’s Post-COVID Priorities Read More »

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s …

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag Read More »

Study finds “alarming” hike in antidepressant costs during COVID-19

Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs. The team from the University of Huddersfield said the findings highlight an “urgent need” for new mental health strategies to make sure antidepressants are being used appropriately, particularly …

Study finds “alarming” hike in antidepressant costs during COVID-19 Read More »

Divided Congress paves way for drug price reforms on Biden’s watch

Unless president Donald Trump is successful with legal challenges, Democratic rival Joe Biden looks to have won the White House in last week’s election but faces the challenges of a divided Congress when it comes to implementing important health policies. Making healthcare affordable is one of Biden’s goals as many Americans struggle to pay for …

Divided Congress paves way for drug price reforms on Biden’s watch Read More »

Pharma may avoid worst-case drug pricing scenario as US elections deadlocked

Pharma may have avoided a worst case scenario amid the political upheavals in the US elections with the threat of tough drug price legislation lowered, with hawkish Democrats unlikely to win overall control of Congress. With the outcome of the presidential race unclear at the time of writing, Democrats likely to back tough drug pricing …

Pharma may avoid worst-case drug pricing scenario as US elections deadlocked Read More »

A Cure at Any Cost? Time to Shine a Light on Drug Pricing

By CECI CONNOLLY and BOBBY CLARK We are all are anxiously awaiting the approval and delivery of a cure to the novel coronavirus – or better yet, a vaccine. Amid the race to develop a safe and effective vaccine, some may be inclined to give drug companies a pass on their well-established bad behavior related …

A Cure at Any Cost? Time to Shine a Light on Drug Pricing Read More »

Policy makers should ‘set their sights higher’ on U.S. drug pricing regulations, researchers say

A review published in JAMA found that bills introduced into the House and Senate don’t go nearly as far as existing drug pricing regulations other countries. The researchers listed eight key lessons from six nations.

Gilead Covid-19 drug remdesivir benefited from $6.5B in NIH-funded basic research, study finds

Research on the drug’s molecular target dates back to the 1950s. A spokesperson for Gilead noted that the company anticipates potentially investing more than $1 billion on the drug this year alone.